论文部分内容阅读
在我国基因治疗的发展上,第一个具有自主知识产权的基因治疗药物“重组人P53腺病毒注射液”,经国家食品药品监督管理局批准,正式用于我国临床。
In the development of gene therapy in our country, the first gene therapy drug “recombinant human P53 adenovirus injection” with independent intellectual property rights was approved by the State Food and Drug Administration and officially used in our country.